DBM
BAMEPHARM
By Aveluro Research Team · Editorial policy
BAMEPHARM (DBM) is a company in Vietnam's Health Care sector, listed on UPCOM. The stock last traded at 27,600 VND, little changed on the session, giving a market capitalization of 46.6 billion VND.
Aveluro tracks 1 news item mentioning DBM, where recent coverage skews positive (100% of articles). The most recent catalyst was a dividend announcement event — "DBM (Dak Lak Pharmaceutical) announced a 35% cash dividend for 2025, with the record date on July 22 and payment on August 6. Major shareholder Traphaco (TRA) will receive about 3.9-4 billion VND.". Aveluro's composite model rates DBM 9.5/10 (Strong Buy), blending news sentiment, price momentum, and fundamentals.
Average daily volume over the past 10 sessions is roughly 12,700 shares; liquidity is relatively thin, so single headlines can move the price sharply. Comparable names in the Health Care sector include AMV, CVN and DAN.
What matters now
DBM (Dak Lak Pharmaceutical) announced a 35% cash dividend for 2025, with the record date on July 22 and payment on August 6. Major shareholder Traphaco (TRA) will receive about 3.9-4 billion VND.
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Want to trade DBM? Compare brokers for Vietnam stocks.
Foreign investors need a broker that can handle Vietnam market access, settlement, custody, and foreign ownership limits.
Aveluro may earn a commission from broker partners. Market data and broker availability can change; confirm access before opening an account.
Low liquidity — thin average daily volume may result in wider spreads and price impact on larger orders.